157
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
56
Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from
fentanyl buccal tablet in cancer patients without oral mucositis: a pilot study. Clin Drug
Invest 2007; 27: 605-611.
57
Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportio-
nality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet
2005; 44: 1279-1286.
58
Davies AN (Hrsg.). Cancer-related breakthrough pain. Oxford: Oxford University Press,
2006.
59
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-
related breakthrough pain: recommendations of a task group of the Science Committee
of the Association for Palliative Medicine of Great Britain and Ireland. European Journal
of Pain 2009; 13(4): 331-338.
60
Davies AN, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D, Fallon M. Consistency of
efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray
compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain
Symptom Manage 2011; 41(2): 358-366.
61
Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology
patients’ utilisation of breakthrough pain medication. Journal of Pain and Symptom
Management 2008; 35(4): 406-411.
62
Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J. Pain Symptom
Manage 2005; 30(6): 496-497.
63
Davies AN, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L,
Sjolund K-F, Stenberg M, Buchanan A. Multi-centre European study of breakthrough
cancer pain: Pain characteristics and patient perceptions of current and potential ma-
nagement strategies. European Journal of Pain 2011; 15: 756-763.
64
Davies AN. Current thinking in cancer breakthrough pain management. Eur J Palliative
Care 2005; 12 (Suppl.): 4-6.
65
Davies AN. General principles of management. In: Davies AN (Hrsg.), Cancer-related
breakthrough pain. Oxford: Oxford University Press; 2006, 31-42.
66
Davies AN. Introduction. In: Davies AN (Hrsg.), Cancer-related breakthrough pain.
Oxford: Oxford University Press; 2006, 1-11.
67
Davies AN. The assessment and measurement of physical pain. In: Hillier R, Finlay I,
Miles A (Hrsg.), The effective management of cancer pain (2. Aufl., 23-28). London:
Aesculapus Medical Press, 2002.
68
Davis MP. Are there cost benefits to fentanyl for breakthrough pain? J Pain Symptom
Manage. 2012 Sep; 44(3): e1-2.
69
Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Review of Neuro-
therapeutics 2011; 11(8): 1197-1216.
70
de Oliveira R, dos Reis MP, Prado WA. the effects of early or late neurolytic sympathetic
plexus block on the management of abdominal or pelvic cancer pain. Pain 2004; 110:
400-408.
Literaturverzeichnis